NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Dapagliflozin, in combination with insulin, for treating type 1 diabetes

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not relevant.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not relevant.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Melinda Goodall…………………

Technology Appraisals: Scoping
Equality impact assessment for the Single Technology Appraisal of dapagliflozin, in combination with insulin, for treating type 1 diabetes
Issue date: August 2018
Equality impact assessment for the Single Technology Appraisal of dapagliflozin, in combination with insulin, for treating type 1 diabetes

Issue date: August 2018